CoChat
Sign Up
Cited by 186

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

MicroRNAs in neurodegenerative diseases and their therapeutic potential

Junn, Eunsung, Mouradian, M. Maral·2012·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2011.10.002PMC PMC3268953
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2011.10.002

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 99

  1. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nature Biotechnology, 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  2. Ambros, 2003, MicroRNAs and other tiny endogenous RNAs in C. elegans, Current Biology, 13, 807, 10.1016/S0960-9822(03)00287-2 · DOI · Paper page
  3. Arai, 2006, TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Biochemical and Biophysical Research Communications, 351, 602, 10.1016/j.bbrc.2006.10.093 · DOI · Paper page
  4. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  5. Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
  6. Beer, 2005, The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair, Oncogene, 24, 5269, 10.1038/sj.onc.1208560 · DOI
  7. Bettens, 2009, APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease, Human Mutation, 30, 1207, 10.1002/humu.21027 · DOI
  8. Bilen, 2006, MicroRNA pathways modulate polyglutamine-induced neurodegeneration, Molecular Cell, 24, 157, 10.1016/j.molcel.2006.07.030 · DOI
  9. Blow, 2007, Small RNAs: delivering the future, Nature, 450, 1117, 10.1038/4501117a · DOI
  10. Bonci, 2008, The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities, Nature Medicine, 14, 1271, 10.1038/nm.1880 · DOI
  11. Brennecke, 2003, bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila, Cell, 113, 25, 10.1016/S0092-8674(03)00231-9 · DOI · Paper page
  12. Bruijn, 2004, Unraveling the mechanisms involved in motor neuron degeneration in ALS, Annual Review of Neuroscience, 27, 723, 10.1146/annurev.neuro.27.070203.144244 · DOI · Paper page
  13. Bumcrot, 2006, RNAi therapeutics: a potential new class of pharmaceutical drugs, Nature Chemical Biology, 2, 711, 10.1038/nchembio839 · DOI
  14. Care, 2007, MicroRNA-133 controls cardiac hypertrophy, Nature Medicine, 13, 613, 10.1038/nm1582 · DOI
  15. Chendrimada, 2005, TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing, Nature, 436, 740, 10.1038/nature03868 · DOI
  16. Chesebro, 2003, Introduction to the transmissible spongiform encephalopathies or prion diseases, British Medical Bulletin, 66, 1, 10.1093/bmb/66.1.1 · DOI
  17. Cohen, 1994, Structural clues to prion replication, Science, 264, 530, 10.1126/science.7909169 · DOI
  18. Cougot, 2004, Cytoplasmic foci are sites of mRNA decay in human cells, The Journal of Cell Biology, 165, 31, 10.1083/jcb.200309008 · DOI
  19. Cruts, 2006, Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, Nature, 442, 920, 10.1038/nature05017 · DOI · Paper page
  20. Davis, 2008, Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus, Journal of Neuroscience, 28, 4322, 10.1523/JNEUROSCI.4815-07.2008 · DOI · Paper page
  21. de Fougerolles, 2007, Interfering with disease: a progress report on siRNA-based therapeutics, Nature Reviews. Drug Discovery, 6, 443, 10.1038/nrd2310 · DOI
  22. de Mena, 2010, FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients, Neuroscience Letters, 479, 22, 10.1016/j.neulet.2010.05.019 · DOI
  23. Doxakis, 2010, Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153, Journal of Biological Chemistry, 285, 12726, 10.1074/jbc.M109.086827 · DOI · Paper page
  24. Eacker, 2009, Understanding microRNAs in neurodegeneration, Nature Reviews Neuroscience, 10, 837, 10.1038/nrn2726 · DOI · Paper page
  25. Ebert, 2007, MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells, Nature Methods, 4, 721, 10.1038/nmeth1079 · DOI · Paper page
  26. Farajollahi, 2010, Molecular diversity through RNA editing: a balancing act, Trends in Genetics, 26, 221, 10.1016/j.tig.2010.02.001 · DOI
  27. Farrer, 2004, Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications, Annals of Neurology, 55, 174, 10.1002/ana.10846 · DOI
  28. Fluiter, 2003, In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides, Nucleic Acids Research, 31, 953, 10.1093/nar/gkg185 · DOI
  29. Fukagawa, 2004, Dicer is essential for formation of the heterochromatin structure in vertebrate cells, Nature Cell Biology, 6, 784, 10.1038/ncb1155 · DOI
  30. Garzon, 2010, Targeting microRNAs in cancer: rationale, strategies and challenges, Nature Reviews. Drug Discovery, 9, 775, 10.1038/nrd3179 · DOI
  31. Gass, 2006, Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration, Human Molecular Genetics, 15, 2988, 10.1093/hmg/ddl241 · DOI
  32. Gehrke, 2010, Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression, Nature, 466, 637, 10.1038/nature09191 · DOI
  33. Gentner, 2009, Stable knockdown of microRNA in vivo by lentiviral vectors, Nature Methods, 6, 63, 10.1038/nmeth.1277 · DOI
  34. Gil, 2008, Mechanisms of neurodegeneration in Huntington's disease, European Journal of Neuroscience, 27, 2803, 10.1111/j.1460-9568.2008.06310.x · DOI
  35. Haramati, 2010, miRNA malfunction causes spinal motor neuron disease, Proceedings of the National Academy of Sciences of the United States of America, 107, 13111, 10.1073/pnas.1006151107 · DOI
  36. Hebert, 2008, Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression, Proceedings of the National Academy of Sciences of the United States of America, 105, 6415, 10.1073/pnas.0710263105 · DOI · Paper page
  37. Hebert, 2010, Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration, Human Molecular Genetics, 19, 3959, 10.1093/hmg/ddq311 · DOI
  38. Hutvagner, 2002, A microRNA in a multiple-turnover RNAi enzyme complex, Science, 297, 2056, 10.1126/science.1073827 · DOI · Paper page
  39. Hwang, 2003, Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice, Brain Research. Molecular Brain Research, 114, 123, 10.1016/S0169-328X(03)00162-1 · DOI
  40. Jadhav, 2009, Antagomirzymes: oligonucleotide enzymes that specifically silence microRNA function, Angewandte Chemie (International Ed. in English), 48, 2557, 10.1002/anie.200805521 · DOI
  41. Johnson, 2008, A microRNA-based gene dysregulation pathway in Huntington's disease, Neurobiology of Disease, 29, 438, 10.1016/j.nbd.2007.11.001 · DOI · Paper page
  42. Kawase-Koga, 2009, Different timings of Dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system, Developmental Dynamics, 238, 2800, 10.1002/dvdy.22109 · DOI
  43. Kim, 2007, A microRNA feedback circuit in midbrain dopamine neurons, Science, 317, 1220, 10.1126/science.1140481 · DOI · Paper page
  44. Kuhn, 2010, Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains, Journal of Biological Chemistry, 285, 1529, 10.1074/jbc.M109.033407 · DOI
  45. Kwiatkowski, 2009, Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis, Science, 323, 1205, 10.1126/science.1166066 · DOI
  46. Landthaler, 2004, The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis, Current Biology, 14, 2162, 10.1016/j.cub.2004.11.001 · DOI
  47. Lee, 2003, The nuclear RNase III Drosha initiates microRNA processing, Nature, 425, 415, 10.1038/nature01957 · DOI
  48. Lee, 2001, An extensive class of small RNAs in Caenorhabditis elegans, Science, 294, 862, 10.1126/science.1065329 · DOI · Paper page
  49. Lee, 2004, MicroRNA genes are transcribed by RNA polymerase II, EMBO Journal, 23, 4051, 10.1038/sj.emboj.7600385 · DOI
  50. Lee, 2004, Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways, Cell, 117, 69, 10.1016/S0092-8674(04)00261-2 · DOI
  51. Lee, 2008, miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis, Nature Neuroscience, 11, 1137, 10.1038/nn.2183 · DOI
  52. Liu, 2010, MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice, Neurobiology of Aging
  53. Liu, 2005, A role for the P-body component GW182 in microRNA function, Nature Cell Biology, 7, 1261, 10.1038/ncb1333 · DOI
  54. Long, 2011, MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed, Biochemical and Biophysical Research Communications, 404, 889, 10.1016/j.bbrc.2010.12.053 · DOI
  55. Lukiw, 2007, Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus, Neuroreport, 18, 297, 10.1097/WNR.0b013e3280148e8b · DOI · Paper page
  56. Mack, 2007, MicroRNA gets down to business, Nature Biotechnology, 25, 631, 10.1038/nbt0607-631 · DOI
  57. Martinat, 2006, Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype, Proceedings of the National Academy of Sciences of the United States of America, 103, 2874, 10.1073/pnas.0511153103 · DOI
  58. Meister, 2004, Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing, RNA, 10, 544, 10.1261/rna.5235104 · DOI
  59. Minones-Moyano, 2011, MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function, Human Molecular Genetics, 20, 3067, 10.1093/hmg/ddr210 · DOI
  60. Montag, 2009, Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease, Molecular Neurodegeneration, 4, 36, 10.1186/1750-1326-4-36 · DOI
  61. Nelson, 2010, MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study, Journal of Alzheimer's Disease, 21, 75, 10.3233/JAD-2010-091603 · DOI · Paper page
  62. Neumann, 2006, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, 130, 10.1126/science.1134108 · DOI · Paper page
  63. Nunes, 2003, Pitx3 is required for development of substantia nigra dopaminergic neurons, Proceedings of the National Academy of Sciences of the United States of America, 100, 4245, 10.1073/pnas.0230529100 · DOI
  64. Nunez-Iglesias, 2010, Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation, PLoS One, 5, e8898, 10.1371/journal.pone.0008898 · DOI
  65. Ohmachi, 2003, Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c, Journal of Neuroscience Research, 72, 436, 10.1002/jnr.10592 · DOI
  66. Ohmachi, 2000, FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain, Biochemical and Biophysical Research Communications, 277, 355, 10.1006/bbrc.2000.3675 · DOI
  67. Orom, 2006, LNA-modified oligonucleotides mediate specific inhibition of microRNA function, Gene, 372, 137, 10.1016/j.gene.2005.12.031 · DOI
  68. Orr, 2007, Trinucleotide repeat disorders, Annual Review of Neuroscience, 30, 575, 10.1146/annurev.neuro.29.051605.113042 · DOI
  69. Paisan-Ruiz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron, 44, 595, 10.1016/j.neuron.2004.10.023 · DOI
  70. Patel, 2008, MicroRNAs can regulate human APP levels, Molecular Neurodegeneration, 3, 10, 10.1186/1750-1326-3-10 · DOI
  71. Pietersen, 2011, Neuronal type-specific gene expression profiling and laser-capture microdissection, Methods in Molecular Biology, 755, 327, 10.1007/978-1-61779-163-5_28 · DOI
  72. Podlisny, 1987, Gene dosage of the amyloid beta precursor protein in Alzheimer's disease, Science, 238, 669, 10.1126/science.2960019 · DOI
  73. Provost, 2010, MicroRNAs as a molecular basis for mental retardation. Alzheimer's and prion diseases, Brain Research, 1338, 58, 10.1016/j.brainres.2010.03.069 · DOI
  74. Rademakers, 2008, Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia, Human Molecular Genetics, 17, 3631, 10.1093/hmg/ddn257 · DOI
  75. Rovelet-Lecrux, 2006, APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy, Nature Genetics, 38, 24, 10.1038/ng1718 · DOI
  76. Saba, 2008, A miRNA signature of prion induced neurodegeneration, PLoS One, 3, e3652, 10.1371/journal.pone.0003652 · DOI · Paper page
  77. Scherr, 2007, Lentivirus-mediated antagomir expression for specific inhibition of miRNA function, Nucleic Acids Research, 35, e149, 10.1093/nar/gkm971 · DOI
  78. Sethupathy, 2008, MicroRNA target site polymorphisms and human disease, Trends in Genetics, 24, 489, 10.1016/j.tig.2008.07.004 · DOI
  79. Sheth, 2003, Decapping and decay of messenger RNA occur in cytoplasmic processing bodies, Science, 300, 805, 10.1126/science.1082320 · DOI
  80. Shioya, 2010, Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3, Neuropathology and Applied Neurobiology, 36, 320, 10.1111/j.1365-2990.2010.01076.x · DOI · Paper page
  81. Singleton, 2003, alpha-Synuclein locus triplication causes Parkinson's disease, Science, 302, 841, 10.1126/science.1090278 · DOI · Paper page
  82. Smith, 2011, MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy, Human Molecular Genetics, 20, 4016, 10.1093/hmg/ddr330 · DOI · Paper page
  83. Son, 2007, Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology, Proceedings of the National Academy of Sciences of the United States of America, 104, 6072, 10.1073/pnas.0610923104 · DOI
  84. Sonntag, 2010, MicroRNAs and deregulated gene expression networks in neurodegeneration, Brain Research, 1338, 48, 10.1016/j.brainres.2010.03.106 · DOI
  85. Stark, 2008, Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model, Nature Genetics, 40, 751, 10.1038/ng.138 · DOI · Paper page
  86. Tam, 2008, Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes, Nature, 453, 534, 10.1038/nature06904 · DOI
  87. Valadi, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nature Cell Biology, 9, 654, 10.1038/ncb1596 · DOI · Paper page
  88. van der Walt, 2004, Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease, American Journal of Human Genetics, 74, 1121, 10.1086/421052 · DOI
  89. Vance, 2009, Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6, Science, 323, 1208, 10.1126/science.1165942 · DOI
  90. Vassar, 2009, The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential, Journal of Neuroscience, 29, 12787, 10.1523/JNEUROSCI.3657-09.2009 · DOI · Paper page
  91. Vilardo, 2010, MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons, Journal of Biological Chemistry, 285, 18344, 10.1074/jbc.M110.112664 · DOI
  92. Vo, 2005, A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis, Proceedings of the National Academy of Sciences of the United States of America, 102, 16426, 10.1073/pnas.0508448102 · DOI · Paper page
  93. Wang, 2011, Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter, Acta Neuropathologica, 121, 193, 10.1007/s00401-010-0756-0 · DOI · Paper page
  94. Wang, 2008, The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1, Journal of Neuroscience, 28, 1213, 10.1523/JNEUROSCI.5065-07.2008 · DOI · Paper page
  95. Wang, 2008, Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein, American Journal of Human Genetics, 82, 283, 10.1016/j.ajhg.2007.09.021 · DOI
  96. Wider, 2009, FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression, Movement Disorders, 24, 455, 10.1002/mds.22442 · DOI
  97. Williams, 2009, MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice, Science, 326, 1549, 10.1126/science.1181046 · DOI · Paper page
  98. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 · DOI
  99. Zuccato, 2003, Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes, Nature Genetics, 35, 76, 10.1038/ng1219 · DOI · Paper page

Cited by

Sorted by citations

See all 186

Metadata

Authors
Junn, E., & Mouradian, M. M.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2012-02
Volume
133
Issue
2
Pages
142-150
ISSN
0163-7258
DOI
10.1016/j.pharmthera.2011.10.002
PMC
PMC3268953
Cited by
186
References
12
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review